Harrow IncNASDAQ:HROW
- LAST PRICE41.3800
- TODAY'S CHANGE (%)-0.6800 (-1.6167%)
- Bid / Lots41.2500/ 6
- Ask / Lots41.4700/ 6
- Open / Previous Close41.9100 / 42.0600
- Day Range
- 52 Week Range
- Volume48,581
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | HROW |
|---|---|---|
| 09:32 ET | 6214 | 41.91 |
| 09:35 ET | 200 | 41.64 |
| 09:37 ET | 391 | 41.8 |
| 09:39 ET | 2400 | 42.39 |
| 09:42 ET | 1700 | 41.6301 |
| 09:44 ET | 517 | 42.093729 |
| 09:46 ET | 200 | 41.82 |
| 09:48 ET | 1100 | 41.85 |
| 09:50 ET | 1081 | 41.39 |
| 09:51 ET | 1096 | 41.1706 |
| 09:53 ET | 204 | 41.396 |
| 09:55 ET | 1600 | 41.3794 |
| 09:57 ET | 870 | 41.6133 |
| 10:00 ET | 100 | 41.54 |
| 10:02 ET | 291 | 41.38 |
| 10:04 ET | 100 | 41.29 |
| 10:08 ET | 200 | 41.445 |
| 10:09 ET | 200 | 41.59 |
| 10:11 ET | 579 | 41.5765 |
| 10:13 ET | 431 | 41.31 |
| 10:15 ET | 100 | 41.35 |
| 10:18 ET | 500 | 41.225 |
| 10:20 ET | 1400 | 41.08 |
| 10:24 ET | 100 | 41.08 |
| 10:26 ET | 2190 | 41.16 |
| 10:27 ET | 4084 | 41.45 |
| 10:29 ET | 2014 | 41.4144 |
| 10:31 ET | 600 | 41.35 |
| 10:33 ET | 100 | 41.4 |
| 10:36 ET | 966 | 41.36 |
| 10:38 ET | 100 | 41.375 |
| 10:40 ET | 776 | 41.47 |
| 10:44 ET | 1900 | 41.57 |
| 10:45 ET | 506 | 41.49 |
| 10:49 ET | 213 | 41.29 |
| 10:51 ET | 200 | 41.38 |
Nov 21, 2024
*DJ Harrow's ImprimisRx Subsidiary Receives $34.9M Unanimous Jury Verdict Award in Case Vs. OSRX Inc., from 7:03AM ET on Thursday Nov 21, 2024 by Dow Jones
7:03AM ET on Thursday Nov 21, 2024 by Dow JonesHarrow's ImprimisRx Subsidiary Receives $34.9 Million Unanimous Jury Verdict Award in ImprimisRx, LLC v. OSRX, Inc., from 7:00AM ET on Thursday Nov 21, 2024 by Dow Jones
7:00AM ET on Thursday Nov 21, 2024 by Dow Jones
Nov 20, 2024
Melt Pharmaceuticals Reports Positive Phase 3 Topline Efficacy Results for MELT-300, Its Lead Product Candidate for Opioid-Free, Sublingual Procedural Sedation in Patients Undergoing Cataract Surgery, from 7:00AM ET on Wednesday Nov 20, 2024 by Dow Jones
7:00AM ET on Wednesday Nov 20, 2024 by Dow Jones
Nov 15, 2024
Harrow Announces Participation in Upcoming Investor Conferences, from 7:00AM ET on Friday Nov 15, 2024 by Dow Jones
7:00AM ET on Friday Nov 15, 2024 by Dow Jones
Nov 14, 2024
DJ Harrow Down Nearly 13%, on Pace for Largest Percent Decrease Since November 2023 -- Data Talk, from 11:46AM ET on Thursday Nov 14, 2024 by Dow Jones
11:46AM ET on Thursday Nov 14, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Harrow Inc | 1.5B | -44.0x | --- |
Ocular Therapeutix Inc | 1.4B | -7.4x | --- |
Immunocore Holdings PLC | 1.6B | -34.7x | --- |
Ligand Pharmaceuticals Inc | 2.3B | 50.1x | -12.71% |
Kiniksa Pharmaceuticals International PLC | 1.5B | -136.6x | --- |
Avadel Pharmaceuticals PLC | 1.1B | -14.1x | --- |
Company Information
Harrow, Inc. is an eyecare pharmaceutical company. The Company is engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the United States market. It provides a comprehensive portfolio of prescription and non-prescription pharmaceutical products. It owns commercial rights to portfolios of branded ophthalmic pharmaceutical products in North America, all of which are marketed under the Harrow name. It owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical-compounding business. It owns United States commercial rights to various products: IHEEZO, VEVYE, TRIESENCE, VIGAMOX, ILEVRO, FLAREX, NATACYN, ZERVIATE and others. VIGAMOX (moxifloxacin hydrochloride ophthalmic solution) 0.5%, a fluoroquinolone antibiotic eye drops for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms. IHEEZO (chloroprocaine hydrochloride ophthalmic gel) 3% is a low-viscosity gel indicated for ocular surface anesthesia.
Contact Information
- Headquarters
- 102 WOODMONT BLVD, SUITE 610NASHVILLE, TN, United States 37215
- Phone
- 615-733-4731
- Fax
- 858-345-1745
Executives
- Chairman of the Board, Chief Executive Officer
- Mark Baum
- Chief Financial Officer, Corporate Secretary
- Andrew Boll
- President and Chief Executive Officer of ImprimisRx, Chief Commercial Officer
- John Saharek
- Lead Independent Director
- Perry Sternberg
- Independent Director
- Adrienne Graves
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.5B |
|---|---|
Revenue (TTM) | $169.1M |
Shares Outstanding | 35.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.70 |
EPS | $-0.94 |
Book Value | $2.01 |
P/E Ratio | -44.0x |
Price/Sales (TTM) | 9.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -5.29% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
